Treats hypertension. ANDA 216420, held by Micro Labs. Nicardipine Hydrochloride.
As of Nov 22, 2026, ANDA 216420 (Nicardipine Hydrochloride), held by Micro Labs, was first approved by FDA on Jul 7, 2023, with 0 approved supplements and 0 published complete response letters.
Nicardipine hydrochloride injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible. 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nicardipine Hydrochloride25MG/10ML (2.5MG/ML) · injectable;injection | Nicardipine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters